首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Utility of immunohistochemical analysis of KAI1, epithelial-specific antigen,and epithelial-related antigen for distinction of chromophobe renal cell carcinoma, an eosinophilic variant from renal oncocytoma
【24h】

Utility of immunohistochemical analysis of KAI1, epithelial-specific antigen,and epithelial-related antigen for distinction of chromophobe renal cell carcinoma, an eosinophilic variant from renal oncocytoma

机译:免疫组织化学分析KAI1,上皮特异性抗原和上皮相关抗原用于区分发色性肾细胞癌的一种方法,该蛋白是肾上皮细胞瘤的嗜酸性变体

获取原文
获取原文并翻译 | 示例
           

摘要

Distinction of renal oncocytoma (RO) from chromophobe renal cell carcinoma (ChRCC) is important because their clinical behavior is different. As part of a search for the best available immunohistochemical markers to distinguish ChRCC from RO, we investigated the immunohistochemical profiles of these tumors. We selected 30 renal tumors consisting of ChRCC, typical variant (n = 14), ChRCC, eosinophilic variant (n = 6), and RO (« = 10). Their expression of cytokeratin (CK) 7, KAI1, epithelial-specific antigen (ESA), epithelial-related antigen (ERA), Claudin-7, and Claudin-8 was studied using an autostainer. Immu-noreactivity was assessed based on a combined score of the extent and intensity of staining. Compared to RO, a significantly higher percentage of the total ChRCCs stained positive for CK7 (85% vs. 10%, respectively), KAI1 (90% vs. 10%), ESA (95% vs. 10%), ERA (95% vs. 10%), and Claudin-7 (95% vs. 20%) (P < 0.001). Additionally, there was a significant difference between the percentage of ChRCC eosinophilic variant (ChRCC-E) and RO that stained positive for KAI1 (100% vs. 10%, respectively), ESA (83% vs. 10%), and ERA (83% vs. 10%) (P < 0.001). We recommend immunohistochemical analysis of KAI1, ESA, and ERA to distinguish ChRCC-E from RO.
机译:区分肾癌和嗜铬肾癌(ChRCC)很重要,因为它们的临床行为不同。为了寻找最佳的免疫组织化学标记物以区分ChRCC和RO,我们调查了这些肿瘤的免疫组织化学特征。我们选择了30种肾肿瘤,包括ChRCC,典型变体(n = 14),ChRCC,嗜酸性变体(n = 6)和RO(«= 10)。使用自动染色仪研究了它们对细胞角蛋白(CK)7,KAI1,上皮特异性抗原(ESA),上皮相关抗原(ERA),Claudin-7和Claudin-8的表达。基于染色程度和强度的综合评分评估免疫反应性。与RO相比,CK7,CK1(90%vs.10%),ESA(95%vs.10%),ERA(95)阳性的ChRCCs显着更高的百分比%vs. 10%)和Claudin-7(95%vs. 20%)(P <0.001)。此外,对KAI1(分别为100%和10%),ESA(83%和10%)和ERA染色呈阳性的ChRCC嗜酸性变体(ChRCC-E)和RO的百分比之间存在显着差异。 83%和10%)(P <0.001)。我们建议对KAI1,ESA和ERA进行免疫组织化学分析,以区分ChRCC-E与RO。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号